Navigation Links
Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures

CAMBRIDGE, Mass., May 22, 2013 /PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on healthcare and sustainability, today announced the appointment of Stephane Bancel as a Senior Partner. In this role, Mr. Bancel will provide strategic counsel and support to portfolio companies.

In addition to working closely with companies in the Flagship portfolio, Mr. Bancel also serves as President and Chief Executive Officer of Moderna Therapeutics, a Flagship VentureLabs™ - founded company.  Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside the patient, within the patient's cells. This allows the in vivo expression of virtually any therapeutic protein for intracellular or systemic action. He is also Executive Chairman of the board for BG Medicine, Inc. (NASDAQ: BGMD), a Flagship portfolio company focused on the discovery, development and commercialization of novel, biomarker-based diagnostics to improve patient outcomes and contain healthcare costs.

"Stephane brings with him a wealth of management experience and expertise in the development and commercialization of medical diagnostic tools and technologies as well as expertise in the pharmaceuticals industry," said Noubar Afeyan , Managing Partner and Chief Executive Officer of Flagship Ventures.  Under Mr. Bancel's leadership, Moderna has entered into one of the largest preclinical biotech-pharma deals in the industry's 35 year history with AstraZeneca. The recently announced partnership agreement involves up to 40 options to drug products and $420M in up front and technology milestone payments. Dr. Afeyan added, "having worked together with Stephane for over three years now at BG Medicine and Moderna, I look forward to seeing his commercial mindset and strategic insights applied more broadly to Flagship's investment strategy as well as to the growth and success of our portfolio companies." 

Mr. Bancel said "What attracted me to Flagship Ventures was the team's depth of experience and knowledge in the life sciences industry, as well as the firm's unique philosophy and approach to realizing entrepreneurial innovation." He continued, "I look forward to building on Flagship's growing reputation as one of the preeminent innovators in the life sciences ecosystem."

Prior to joining Flagship, Mr. Bancel served as Chief Executive Officer of bioMerieux (NYSE Euronext: BIM.PA), a world leader in the diagnostics industry. During his five years leading the company, he accelerated the sales growth rate, enhanced its position as a global leader in clinical microbiology and re-accelerated its immunoassay franchise by focusing on high medical value biomarkers. Under his leadership, the company's market capitalization nearly doubled despite the broader economic downturn.

Previously, Mr. Bancel was Managing Director of Eli Lilly in Belgium and Executive Director of Global Manufacturing Strategy and Supply Chain at Eli Lilly in Indianapolis. He earned a Master of Engineering from Ecole Centrale Paris, a Master of Science in Chemical Engineering from the University of Minnesota and an MBA from Harvard Business School. In 2009, Mr. Bancel was elected a Young Global Leader by the World Economic Forum. He was elected Best CEO for Investor Relations in France in 2009 and was ranked #1 CEO in the Biotechnology sector according to the 2011 Thomson Reuters Pan European EXTEL Study.

About Flagship Ventures
Realizing entrepreneurial innovation is the mission of Flagship Ventures. The firm operates through two synergistic units: VentureLabs™ which invents and launches transformative companies, and Venture Capital, which finances and develops innovative, early-stage companies. Founded in 2000, and based in Cambridge, Massachusetts, Flagship Ventures manages over $900 million in capital. The Flagship team is active in three principal business sectors: therapeutics, health technologies and sustainability/clean technology. Past successful Flagship portfolio companies include:  Accuri Cytometers (acquired by Becton, Dickinson and Company), Adnexus (acquired by Bristol-Myers Squibb), Hypnion (acquired by Eli Lilly), AVEO (NASDAQ: AVEO), BG Medicine (NASDAQ: BGMD), Tetraphase (NASDAQ: TTPH), Receptos (NASDAQ: RCPT) and Morphotek (acquired by Eisai).  Additional notable portfolio companies include:  AeroDesigns, Affinnova, Agios, BIND Therapeutics, Joule Unlimited, Quanterix, and Moderna Therapeutics.  For more information, please visit

 Contact:For Flagship Ventures: 

Rachel BrennerRuder Finn212.715.1623 

SOURCE Flagship Ventures
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
2. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
3. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
4. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
5. Fuse Science Partners With GNC To Open National Distribution Of EnerJel™
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
7. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
8. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
9. Neurocrine Biosciences Reports First Quarter 2012 Results
10. Remedy Informatics Named "Cool Vendor" in Life Sciences by Leading Technology Analyst Firm
11. Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic
Post Your Comments:
(Date:11/29/2015)... , Nov. 29, 2015 CIVCO ... guidance technology at the Radiological Society of ... Chicago November 29 – ... is designed to offer customers unrivaled versatility, enhanced ... --> ...
(Date:11/27/2015)... November 27, 2015 Ein ... fortgeschrittenem Krebs.   --> Ein neuer ... Krebs.   --> Ein neuer ... Krebs.   Clinical Cancer Research ... Clinical Cancer Research vom 6. November 2015 ...
(Date:11/26/2015)... , November 27, 2015 ... --> --> ... emergency response system (PERS) market ... for 5 years with APAC ... expected to see a high ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back again ... choose from, the possibilities are endless. Users have full control over angle of view, ... masking effects, users are sure to get heads to turn. , ProPanel: Pulse offers ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... care in America. As people age, more care is needed, especially with Alzheimer’s, ... and medical professionals are being overworked. The forgotten part of this equation: 80 ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with ... digital component is distributed nationally, through a vast social media strategy and across ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by ... of issues that are presently affecting Americans. Dedicated to providing the world with a ... the subjects consumers focus on, one episode at a time. , In the ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... ... California Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at ... They observed that both STEMI and Sepsis conditions present in similar ways and require ...
Breaking Medicine News(10 mins):